%0 Journal Article
%@ 2379-3708
%A Ogbe, A
%A Pace, M
%A Bittaye, M
%A Tipoe, T
%A Adele, S
%A Alagaratnam, J
%A Aley, PK
%A Ansari, MA
%A Bara, A
%A Broadhead, S
%A Brown, A
%A Brown, H
%A Cappuccini, F
%A Cinardo, P
%A Dejnirattisai, W
%A Ewer, KJ
%A Fok, H
%A Folegatti, PM
%A Fowler, J
%A Godfrey, L
%A Goodman, AL
%A Jackson, B
%A Jenkin, D
%A Jones, M
%A Longet, S
%A Makinson, RA
%A Marchevsky, NG
%A Mathew, M
%A Mazzella, A
%A Mujadidi, YF
%A Parolini, L
%A Petersen, C
%A Plested, E
%A Pollock, KM
%A Rajeswaran, T
%A Ramasamy, MN
%A Rhead, S
%A Robinson, H
%A Robinson, N
%A Sanders, H
%A Serrano, S
%A Tipton, T
%A Waters, A
%A Zacharopoulou, P
%A Barnes, E
%A Dunachie, S
%A Goulder, P
%A Klenerman, P
%A Screaton, GR
%A Winston, A
%A Hill, AVS
%A Gilbert, SC
%A Carroll, M
%A Pollard, AJ
%A Fidler, S
%A Fox, J
%A Lambe, T
%A Frater, J
%D 2022
%F discovery:10184137
%I American Society for Clinical Investigation
%J JCI Insight
%K AIDS/HIV, Adaptive immunity, COVID-19, Cellular immune response, T cells, COVID-19, ChAdOx1 nCoV-19, HIV Infections, Humans, Male, SARS-CoV-2, Vaccination
%N 7
%T Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
%U https://discovery.ucl.ac.uk/id/eprint/10184137/
%V 7
%X Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
%Z Copyright: © 2022, Ogbe et al. This is an open access article published under the terms of the Creative CommonsAttribution 4.0 International License.